Amgen Re-Ups Investment In Sutro Biopharma

The venture capital arm of Thousand Oaks-based Amgen has placed more funding into one of its portfolio companies, Sutro Biopharma, which is working on developing a scalable biochemical protein synthesis platform aimed at cancer therapeutics. Sutro said it has raised $16.5M in a second tranche of its Series C funding, which was led by Skyline Ventures, and also included Lilly Ventures, Amgen Ventures, SV Life Sciences and Alta Partners. Amgen has been an investor in Sutro since at least 2010. Sutro is based in South San Francisco. More information »